Yoriko Yamashita-Kashima
5PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 27, 2025
Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.Natsumi Kawasaki, Sei Shu, Mayu Tomita
|Aug 07, 2023
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.Natsumi Kawasaki, Mayu Tomita, Yoriko Yamashita-Kashima
|Mar 18, 2022
Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.Yoriko Yamashita-Kashima, Keigo Yorozu, Takaaki Fujimura
|Feb 26, 2022
Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.Natsumi Kawasaki, Yoriko Yamashita-Kashima, Takaaki Fujimura
|Apr 14, 2021
Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki
Pageof 1
